Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
August 2026 in Oncology: A Look Back at FDA Approvals and Decisions
2
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
3
Hypoxia Tracer Gets FDA Breakthrough Status in HPV+ Oropharyngeal Cancer
4
New Risk Index Sharpens Outcome Prediction After Fixed-Duration CLL Therapy
5